Bregman Jana A, Herren David J, Estopinal Christopher B, Chocron Isaac M, Harlow Paula A, Warden Cassandra, Brantley Milam A, Samuels David C
Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Vanderbilt Genetics Institute and Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States.
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1346-1351. doi: 10.1167/iovs.16-20616.
We previously reported European mitochondrial haplogroup H to be a risk factor for and haplogroup UK to be protective against proliferative diabetic retinopathy (PDR) among Caucasian patients with diabetic retinopathy (DR). The purpose of this study was to determine whether these haplogroups are also associated with the risk of having DR among Caucasian patients with diabetes.
Deidentified medical records for 637 Caucasian patients with diabetes (223 with DR) were obtained from BioVU, Vanderbilt University's electronic, deidentified DNA databank. An additional 197 Caucasian patients with diabetes (98 with DR) were enrolled from the Vanderbilt Eye Institute (VEI). We tested for an association between European mitochondrial haplogroups and DR status.
The percentage of diabetes patients with DR did not differ across the haplogroups (P = 0.32). The percentage of patients with nonproliferative DR (NPDR; P = 0.0084) and with PDR (P = 0.027) significantly differed across the haplogroups. In logistic regressions adjusting for sex, age, diabetes type, duration of diabetes, and hemoglobin A1c, neither haplogroup H nor haplogroup UK had a significant effect on DR compared with diabetic controls. Haplogroup UK was a significant risk factor (OR = 1.72 [1.13-2.59], P = 0.010) for NPDR compared with diabetic controls in the unadjusted analysis, but not in the adjusted analysis (OR = 1.29 [0.79-2.10], P = 0.20).
Mitochondrial haplogroups H and UK were associated with severity, but not presence, of DR. These data argue that the effect of these haplogroups is related to ischemia and neovascularization, the defining features of PDR.
我们之前报道过,在患有糖尿病视网膜病变(DR)的白种人患者中,欧洲线粒体单倍群H是增殖性糖尿病视网膜病变(PDR)的一个风险因素,而单倍群UK具有保护作用。本研究的目的是确定这些单倍群是否也与患有糖尿病的白种人患者发生DR的风险相关。
从范德堡大学的电子匿名DNA数据库BioVU中获取了637名患有糖尿病的白种人患者(223名患有DR)的去识别化医疗记录。另外从范德堡眼科研究所(VEI)招募了197名患有糖尿病的白种人患者(98名患有DR)。我们测试了欧洲线粒体单倍群与DR状态之间的关联。
糖尿病患者中患有DR的比例在各单倍群之间没有差异(P = 0.32)。非增殖性DR(NPDR;P = 0.0084)和PDR患者的比例在各单倍群之间有显著差异(P = 0.027)。在对性别、年龄、糖尿病类型、糖尿病病程和糖化血红蛋白进行校正的逻辑回归分析中,与糖尿病对照组相比,单倍群H和单倍群UK对DR均无显著影响。在未经校正的分析中,与糖尿病对照组相比,单倍群UK是NPDR的一个显著风险因素(比值比[OR] = 1.72 [1.13 - 2.59],P = 0.010),但在校正分析中并非如此(OR = 1.29 [0.79 - 2.10],P = 0.20)。
线粒体单倍群H和UK与DR的严重程度相关,但与DR的发生无关。这些数据表明,这些单倍群的作用与缺血和新生血管形成有关,而缺血和新生血管形成是PDR的特征性表现。